<--GAT-->
Clinical Topics

Adjuvant Chemotherapy Improves Survival in Rectal Cancer

by U.S. Medicine

June 15, 2018

DURHAM, NC — The standard of care for locoregionally advanced rectal cancer (LARC) in the United States usually involves adjuvant chemotherapy (AC) following chemoradiation (CRT) and total mesorectal excision (TME).

The concern raised by a new study in the Journal of Clinical Oncology, however, is that data proving benefits have been lacking.1

Researchers from the Durham, NC, VAMC and Duke University Medical Center sought to remedy that, by examining the role, optimal regimen and duration of AC in the mandatory, prospectively collected cancer registry of the largest integrated health system in the United States.

To accomplish that, the study team used the VA Central Cancer Registry, including Stage II-III rectal cancer patients diagnosed between January 2001 and April 2011, if they received neoadjuvant CRT, followed by TME, with or without AC.

At least four months of therapy was defined as “adequate chemotherapy,” and survival outcomes were compared. Overall, 649 patients were identified, with 323 receiving AC, while 326 did not (OBS). For the mostly white and male group, mean age 63, median follow-up was 66 months. Almost half of the patients, 49.2% had Stage II disease.

Results indicated that median overall survival (OS) for all patients was 92 months, with six-year OS at 56.8%. Median OS was 72 months for the OBS group and not reached (NR) for the AC group (p < 0.001).

Six-year OS was 49.5% for OBS and 64.1% for AC (p < 0.0001). On PS matched analysis, OS was improved, favoring AC (p < 0.0001).

The researchers reported that median disease-specific survival (DSS) was NR for the whole group and NR for the OBS and AC groups. At six years, DSS was 73.6% for the whole group and 67.9% for OBS vs. 79.2% for AC (p < 0.001). The study team concluded that PS matched analysis for DSS favored AC (p = 0.0004).

No significant difference was detected in OS (p = 0.554) or DSS (p = 0.680) when comparing single vs. multiagent chemotherapy and no significant difference in OS (p = 0.766) or DSS (p = 0.271) when comparing adequate vs. inadequate chemotherapy.

“In this VA population of LARC patients treated with neoadjuvant CRT followed by TME, the addition of AC was found to improve both OS and DSS compared to OBS,” the study authors concluded. “There was no improvement in OS or DSS with the addition of a multi-agent over single-agent chemotherapy.”


1Spiegel D, Boyer M, Hong JC, Williams CD, e. al. Role of adjuvant chemotherapy following chemoradiation and surgery for locoregionally advanced rectal cancer: A Veterans Health Administration analysis. Journal of Clinical Oncology 2018 36:4_suppl, 741-741.

Related Articles

“Coming together is a beginning. Keeping together is progress. Working together is success.” — Henry Ford (1863-1947)

October is Operation Bushmaster season for Uniformed Services University (USU) medical and nursing students.

NASA Partners with Academia for CVD Prediction Tool in Younger Adults

Federal medicine played a crucial role in the development of a new online tool to better predict which middle-aged adults are at the greatest risk of having acute myocardial infarction or stroke over the next decade.


U.S. Medicine Recommends


More From oncology

Oncology

VA/National Cancer Institute Partnership Increases Veteran Access to Trials

Thanks to a new partnership between the National Cancer Institute and the VA, veterans with cancer will now have greater access to potentially lifesaving clinical trials.

Oncology

VA Continues Hepatocellular Screening, but Study Questions the Value

Although a recent study determined that screening veterans with cirrhosis for hepatocellular carcinoma did not reduce the risk of death associated with liver cancer, the VA has no plans to change its screening practices.

Oncology

Testosterone Therapy Not Linked to Aggressive Prostate Cancer in Veterans

Clinicians prescribing supplemental testosterone in men with low levels always have a nagging concern about the possible link between increasing hormone levels and prostate cancer.

Oncology

Side-effects Differ Between Radiation Therapies for Prostate Cancer

A recent study compared patient-reported disease-specific functional outcomes after external beam radiation therapy (EBRT) and EBRT combined with low-dose-rate brachytherapy prostate boost (EB-LDR) among men with localized prostate cancer.

Oncology

Parkinson's Drug Not Associated With Higher Prostate Cancer Risk

An increased incidence of prostate cancer was observed in Parkinson's disease (PD) patients treated with entacapone during a pre-approval randomized clinical trial, according to a new study which noted that the relationship had not yet been intensely investigated.

Facebook Comment

Subscribe to U.S. Medicine Print Magazine

U.S. Medicine is mailed free each month to physicians, pharmacists, nurse practitioners, physician assistants and administrators working for Veterans Affairs, Department of Defense and U.S. Public Health Service.

Subscribe Now

Receive Our Email Newsletter

Stay informed about federal medical news, clinical updates and reports on government topics for the federal healthcare professional.

Sign Up